Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526070 · ClinicalTrials.gov registry record
Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
A clinical trial of Exudative Age-Related Macular Degeneration, sponsored by Stanford University.
- Completed
- Registry status
- 142
- Enrollment target
- 1
- Study location
NCT01526070 is a study of Exudative Age-Related Macular Degeneration that has completed, run by Stanford University. The registered enrollment target is 142 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01526070, a study of Exudative Age-Related Macular Degeneration, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks. In contrast, clinical trials of a soluble VEGF receptor, Aflibercept/VEGF Trap-Eye (Eylea, Regeneron Pharmaceuticals) have demonstrated maintained anatomic and visual improvement with many fewer injections (typically monthly injections for 3 months, followed by every-other-month injections, and as few as 5 injections a year). The purpose of this study is to determine whether patients who have switched from ranibizumab to VEGF Trap-Eye have comparable results.
Conditions Studied
Interventions
- DRUG Intravitreal injection of Aflibercept
Study Locations (1)
California
- Byers Eye Institute at Stanford - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01526070
The ClinicalTrials.gov registry entry for NCT01526070 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Exudative Age-Related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Intravitreal injection of Aflibercept is the first listed.
NCT01526070 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01526070 about?
NCT01526070 is a clinical study titled "Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration". Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks. In contrast, clinical trials of a soluble VEGF receptor, Aflibercept/VEGF Trap-Eye (Eyle...
What is the current status of trial NCT01526070?
This trial is currently completed. The enrollment target is 142 participants. The study started on 2012-01. Estimated completion is 2014-07.
What conditions does trial NCT01526070 study?
This clinical trial studies the following conditions: Exudative Age-Related Macular Degeneration.
What interventions are being tested in trial NCT01526070?
The interventions under investigation include: Intravitreal injection of Aflibercept (DRUG).
Who is sponsoring clinical trial NCT01526070?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01526070 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exudative Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.